[Editor’s Note: As we have communicated previously, we generally do not cover, and certainly do not endorse, market research or similar studies for sale. We do take note of data promoting such research if it informs general understanding and is linked to ethical and policy issues related to vaccines the Center is following]
Research and Markets: Opportunity Analysis of H1N1 (swine flu) Vaccination Market – The Global H1N1 Influenza Vaccine Market is Estimated to be at 676 Million in 2009
“…The first movers in the vaccines market (for H1N1) are GlaxoSmithKline (GSK), Novartis, CSL, Medimmune, Baxter, Sinovec and Sanofi Pastuer. Medimmune is the only producer of the intranasal vaccine whereas other companies are expected to come out with intramuscular vaccines. The companies have got approvals for their first lots from the governments of the various countries such as U.S., U.K., France, China, Denmark and Australia. The involvement of government bodies, increased awareness about prevention and pandemic situation of the influenza is driving the market for the vaccines.
“…The global H1N1 Influenza vaccine market is estimated to be of 676 million in 2009 with first lot of doses being commercialized on 30th September 2009. The market will see a high CAGR for the next two years i.e. the market is expected to be at $7.03 billion in 2011 with a CAGR of 222.4% from 2009 to 2011. However, the very high CAGR will settle down by 2012 to 30% for the period of 2009 to 2012. The reason for the sudden settle down of the growth is that it is expected that most of the world population will be immunized by the end of 2011.”
vaccines and global health :: ethics and policy 